Éric Assenat

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

Étienne Garin, Lambros Tselikas, Boris Guiu et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 604 citations

Medicine, Oncology, Radiation Oncology +17

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Shukui Qin, Masashi Kudo, T Meyer et al. · Annals of Oncology · 2022 · 66 citations · Full text

Medicine, Oncology, Pharmacology +13

Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial

Étienne Garin, Lambros Tselikas, Boris Guiu et al. · Journal of Nuclear Medicine · 2024 · 44 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

George Lau, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng et al. · Journal of Hepatology · 2024 · 36 citations · Full text

Medicine, Oncology, Pharmacotherapy +13